We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Through-Wave Ultrasound Shown To Be Effective for Breast Imaging and Biopsy

By Biotechdaily staff writers
Posted on 11 Dec 2007
A real-time through-wave ultrasound imaging system that uses the diffractive properties of sound combined with holography (HU) to create highly-detailed, three-dimensional images of breast tissue, is now equipped for image-guided biopsy. More...


Advanced Imaging Technologies (Richland, WA, USA) reported that the Aria Breast Imaging system (BIS) has been clinically proven to provide superior views of the breast tissue, especially dense tissue, while providing better data for enhanced diagnostic decision-making. The automated system's image-guidance for biopsy was recently demonstrated at the annual meeting of the Radiological Society of North America (RSNA) November 25-29, 2007, in Chicago, IL, USA.

Until now, women with dense breast tissue have had few options, as mammography is ineffective for dense tissue. This is significant given the link between tissue density and breast cancer documented in a study published in the January 18, 2007, issue of the New England Journal of Medicine (NEJM).

The Aria BIS effectively penetrates dense tissue, is automated with whole-breast presentation capabilities, and provides high spatial and contrast resolution. Moreover, the system allows for retrieval of earlier comparative studies for quick cross-correlation with known landmarks for year-to-year comparison.

"Our technology has proven to have superior spatial and contrast resolution, especially in dense tissue,” said Jeanette Griscavage-Ennis, Ph.D., manager, clinical applications. "The data we capture is saturated with critical information that is important for diagnostic procedures such as biopsy. Our real-time image-guidance capabilities provide physicians with precision for improved biopsy accuracy.”

Breast imaging has become a multimodality process intended to improve detection, diagnosis and staging of breast cancer. The result is earlier detection and improved outcomes for thousands of women. However, use of multiple modalities has real economic implications for workflow and efficiency. Low reimbursement rates make it difficult for imaging centers to stay financially sound and although demand for breast imaging services has increased, the numbers of imaging clinics has decreased.

Minimally operator dependent, the system combines the critical elements of multiple modalities into a single system that integrates easily into the patient work-up while improving workflow and efficiency. The system is picture archiving and communication system (PACS)/Digital Imaging and Communications in Medicine
(DiCOM)-compliant and features a flexible workstation that interfaces easily with multiple imaging and reporting systems.

The Aria BIS is U.S. Food and Drug Demonstration- (FDA)-cleared for breast imaging and image-guided breast biopsy.


Related Links:
Advanced Imaging Technologies

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.